FDA 483 - Shaanxi Hanjiang Pharmaceutical Group Co., Ltd (Gaoxin site) - September 18, 2023
Shaanxi Hanjiang Pharmaceutical Group Co., Ltd. in Hanzhong City, China, an animal drug API manufacturer, was cited for four observations during an FDA inspection. The inspection revealed deficiencies in laboratory OOS/OOT procedures, inadequate investigation of discrepancies like shipping complaints, insufficient detail in written procedures for cleaning and raw material sampling, and incomplete production records. These issues indicate a need for improved quality control and documentation practices.
- Inspection date
- September 18, 2023
- Product type
- drugs
ID · d66ee45e-1e72-4f38-9d07-93784a1b2d0a
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.